Bayer to acquire rights to Algeta's cancer drug

09/4/2009 | Bloomberg

Bayer offered to buy the rights to Algeta's cancer drug Alpharadin for as much as $800 million. Alpharadin, which is undergoing trials as a treatment for bone metastasis in prostate cancer patients, works by sending out radioactive molecules straight to tumor sites without affecting healthy tissue.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care